VA San Diego Healthcare Systems, San Diego, CA

Is VA San Diego Healthcare Systems registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does VA San Diego Healthcare Systems hold a California pharmacy license?

No license with this exact name and city was found in the California State Board of Pharmacy file dated Nov 6, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file lists current licenses only, not revoked, surrendered or cancelled ones.

Has VA San Diego Healthcare Systems had a state board action or FDA letter?

FDA letters: no matching record found on FDA’s compounding inspections and actions page (current as of Oct 22, 2026, covering 2019 on) on Nov 15, 2026; the page lists 1 Form 483 (May 8, 2026) for VA San Diego Healthcare Systems. State board actions: no California State Board of Pharmacy action under this exact name and city was found in the board’s posted disciplinary decisions on facility licenses (actions dated Jan 5, 2005 to Oct 28, 2026) on Nov 6, 2026.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
VA San Diego Healthcare Systems
Location
San Diego, CA
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
May 8, 2026
FDA Data Dashboard inspections
No matching site found
Form 483 text on this page
1 Form 483, 11 observations
State board records
No exact match

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as VA San Diego Healthcare Systems, a 503A facility, with 1 dated action.

Document
May 8, 2026Form 483483 Issued 05/08/2026fda.gov

A Form 483 lists investigator observations, not a final FDA determination.

FDA inspection classifications and published Form 483s

No inspected site under this exact name and city was found in the FDA Data Dashboard on Nov 15, 2026, searching 12,593 US sites with a drug inspection ending Oct 1, 2008 to Oct 23, 2026. FDA may list the site under another legal name, so this is not a finding that it was never inspected.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 11 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Apr 27, 2026 to May 8, 2026: 11 observations

Firm on the cover
VA San Diego Healthcare Systems, 3350 La Jolla Village Dr, San Diego, CA 92161-0002
FEI number
2071629
Establishment type on the cover
Producer of Sterile Drug Products
FDA district office on the cover
19701 Fairchild Irvine, CA 92612-2445
Matched to this page by
firm name, city and state on the cover; linked from actions page
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Smoke studies were inadequately performed under dynamic conditions.

Specifically,

Your firm did not conduct smoke studies under dynamic conditions, simulating worst-case production activities, including all components, materials, and equipment present during actual or routine aseptic operations, to demonstrate unidirectional airflow within the ISO 5 area(s) for the following equipment:

04/08/2026 -Hazardous - <Redacted B4> -Biologic Safety Cabinets (BSC) -SN: <Redacted B4> J 03/11/2026 -Non-Hazardous - <R edacted B4> -Laminar Flow Hood (LAFH ) -SN: <Red acted B4> and <Redacted B4> 04/23/2026 -Operating Room (OR) Segregated - <Redacted B4> -Compounding Aseptic <Redacted B4> <Redacted B4> SN: <Redacted B4>

04/23/2026 -Intensive Care Unit (ICU) Segregated <Redacted B4> - Compounding Aseptic <Redacted B4> - SN: <Redacted B4>

Add Continuation Page

A) For example, your smoke study of the sterile hazardous room (room <Redacted B4> ) did not introduce smoke to visualize airflow at the equipment and workflow management system containing the scale and camera for production operations. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Beta-lactam drugs were produced without providing adequate containment, segregation, and/or cleaning of work surfaces, utensils, and/or personnel to prevent cross-contamination.

Specifically,

Beta-Lactam drug products are produced in the same ISO 5 hoods as non-beta-lactam drug products intended to be sterile. The following beta-lactam drugs were observed being produced in your LAFH hood include, but are not limited to:

ceftaroline fosamil 300 mg in D5W 100 mL

ampicillin 2 gm in Normal Saline Mini-Bag 100 mL

ampicillin/sulbactam 3 gm in Normal Saline Mini-Bag I00 mL

ertapenem I gm in Normal Saline Mini-Bag 50 mL

meropenem 1000 mg in Normal Saline Mini-Bag 50 mL

meropenem 2000 mg in Normal Saline 100 mL

Your firm performs cleaning with only '(bl <41 between the production ofbeta-lactam and non-beta lactam drug products intended to be sterile in the same ISO 5 area and uses[(I:)) (4) I, with a [(I:)) (4) I~ time, as the cleaning/sanitizing agent to inactivate beta-lactam residues only[(I:)) (4) Ion[(I:)) (4) Iin the non-hazardous production area. This frequency is inadequate to prevent cross-contamination.

Add Continuation Page

Observation 3

Contamination was observed in your production area.

Specifically,

On 04/29/2026, unidentified brown staining was observed on the HEPA filter in the ISO 5 non-hazardous LAFH production hood (SN: <Redacted B4>. Your firm was unable to identify the source of the staining or confirm whether it affected filter integrity, air quality, or aseptic conditions in the ISO 5 area. The duration of this condition is unknown.

Add Continuation Page

Observation 4

Lack of disinfection of supplies at each transition from areas of lower quality air to areas of higher quality air.

Specifically,

A) On 04/27/2026, 04/28/2026, and 04/29/2026, <Redacted B4> operators in both the hazardous and non-hazardous production rooms failed to wipe down materials with an appropriate disinfectant (e.g., <Redacted B4> when transitioning those materials from the ISO 7 buffer room environment into the ISO 5 critical zone during the production of luspatercept aamt 50mg, label # <Redacted B4>

B) On 04/28/2026, a re-purposed <Redacted B4> bottle, labeled <Redacted B4> used to discard leftover fluid generated during aseptic processing operations, was observed used within the ISO 5 critical zone without observed disinfection upon transfer from the ISO 7 buffer room after being emptied. The bottle was reused and stored in the ISO 5 hood over multiple days. During aseptic processing activities, the cap has to be removed by the technician, and the bottle handled each time liquid is deposited inside. The operator was observed discarding liquid into the reused bottle. ...

Read the full 483 (PDF on fda.gov)

Observation 5

An operator rested their arms on the work surface of the hood during aseptic production. This practice may introduce contamination into the ISO 5 work area.

Specifically,

A) In the non-hazardous production room <Redacted B4> operators were observed resting their hands directly on the ISO 5 workbench surface on 04/29/2026 during the production of micafungin 100mg in normal saline 1OOmL.

B) On 04/28/2026, the operator's elbows were observed resting on the edge of the front grille of the ISO 5 Biological Safety Cabinet (BSC).

Add Continuation Page

Observation 6

Personnel were observed touching equipment or other surfaces located outside of the ISO 5 area with gloved hands and then proceeding with aseptic processing without changing or sanitizing gloves.

Specifically,

On 04/28/2026 during the production of bortezomib 2.7mg, label # <Redacted B4> an operator failed to sanitize or change their gloved hands with <Redacted B4> after touching the computer keyboard and mouse within the ISO 7 buffer room prior to going back into the ISO 5 critical area to continue aseptically processing drug product intended to be sterile.

Your SOP only specifies <Redacted B4> surfaces. We did not observe your third party cleaners cleaning and sanitizing your keyboards, mouse, and handheld scanner.

Add Continuation Page

Observation 7

Personnel were observed moving quickly in a critical area or in an area immediately adjacent to a critical area likely causing disruption of unidirectional airflow.

Specifically,

An operator was observed spraying their gloved hands with (bl <4> under the ISO 5 hood and then rapidly moved their hands to dry within the critical area, causing disruption of unidirectional airflow on 04/28/2026 during the production of bortezomib 2.7mg, label li(o) (4) The operator's hands moved rapidly over materials and components used during production.

Add Continuation Page

Observation 8

Production areas have difficult to clean or contain porous, particle generating, or visibly dirty equipment or surfaces.

Specifically,

A) The <Redacted B4> plate and washer located on the front grille of BSC SN: <Redacted B4> and <Redacted B4> (hazardous room <Redacted B4> ) are difficult to clean and may harbor and shed particulates and microbial contamination into the ISO 5 environment. This screw and washer were left by the firm's engineering to the BSC grill and not part of the smoke studies, therefore there is no assurance that this is not interfering in the functionality or causing turbulence in the BSC.

B) On 04/30/2026, during the production of doxorubicin 48mg in normal saline 250 mL, chipped and protruding paint was observed on the walls ofthe ISO 7 buffer room.

C) At least <Redacted B4> protruding fire sprinklers located in the ISO 7 ante and buffer rooms were observed not cleaned since around 2020. Additionally, the screw, cameras, and WiFi device on the ceilings of the buffer rooms (room <Redacted B4> were not documented as cleaned. The buffer rooms contain the ISO 5 areas that are used to produce drug products intended to be sterile. ...

Read the full 483 (PDF on fda.gov)

Observation 9

Personnel performed aseptic manipulations with exposed hair or skin.

Specifically,

A) On 04/27/2026 and 04/29/2026, multiple operators were observed aseptically processing drug products intended to be sterile in the ISO 5 laminar airflow hood (LAFH) with exposed hair, including during the production of daptomycin 670 mg in sodium chloride 0.9%, 36.6 mL, label # <Redacted B4> in room <Redacted B4>

B) On 04/29/2026, one operator was observed inserting their head, including the exposed skin of their forehead, and eyeglasses into the ISO 5 critical zone during the production of luspatercept-aamt 50mg, label <Redacted B4>. These eyeglasses are only cleaned with <Redacted B4> before being brought into the ISO 7 buffer area and are worn throughout the hospital and patient care areas. No sporicidal agent was used to clean these items and no environmental monitoring was performed to assess the contamination risk they may introduce.

Add Continuation Page

Observation 10

Materials were exposed to lower than ISO 5 quality air.

Specifically,

A) Sterile, lint-fre.e wipes stored in an exposed, open condition were observed on the wall of the ISO 7 buffer rooms. At least <Redacted B4> of the transparent boxes on the wall had broken hinges and were left open during production. The wipes, which were difficult to pull from the box, were sprayed with sterile <Redacted B4> in the ISO 7 buffer and then used to clean the ISO 5 workbench surface and to wipe materials transitioning from areas of lower quality air into the ISO 5 critical areas.

B) Sterile, lint-free wipes were observed on the wall of the unclassified areas of the segregated ICU room <Redacted B4> by the sink.

Add Continuation Page

Observation 11

Personnel engaged in aseptic processing were observed wearing non-sterile gloves.

Specifically,

Operators were observed using expired sterile gloves (manufactured in 01/2022) during aseptic production of bortezomib 2.7mg, label # <Redacted B4> on 04/28/2026. There is no assurance that the gloves are intact and remain sterile.

Your sterile glove manufacturer suggested that the gloves be used within <Redacte d B4> of the manufacturer date.

Add Continuation Page

State board of pharmacy records

No license with this exact name and city was found in the California State Board of Pharmacy file dated Nov 6, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file lists current licenses only, not revoked, surrendered or cancelled ones. Board file.

What this covers: Facility license decisions from the board’s quarterly Disciplinary Actions pages (87 of 88 quarters had a facility section). These are final decisions; accusations filed and immediate protection orders are not included. Actions in the data are dated Jan 5, 2005 to Oct 28, 2026.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.